Intercept Pharmaceuticals Inc (ICPT): Lisa Bright , officer of Intercept Pharmaceuticals Inc sold 251 shares on May 25, 2016. The Insider selling transaction was reported by the company on May 26, 2016 to the Securities and Exchange Commission. The shares were sold at $137.50 per share for a total value of $34,511.95 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 4, 2016, Rachel Mcminn (Chief Strategy Officer) sold 130 shares at $147.49 per share price.On Apr 7, 2016, Mark Pruzanski (CEO & President) sold 708 shares at $130.76 per share price.Also, On Apr 6, 2016, David Shapiro (CMO and EVP – Development) sold 165 shares at $130.76 per share price.On Apr 6, 2016, Lisa Bright (officer ) sold 153 shares at $130.76 per share price.
Intercept Pharmaceuticals Inc: On Wednesday, May 25, 2016 heightened volatility was witnessed in Intercept Pharmaceuticals Inc which led to swings in the share price. The shares opened for trading at $140.02 and hit $142.745 on the upside , eventually ending the session at $141.21, with a gain of 1.01% or 1.41 points. The heightened volatility saw the trading volume jump to 3,87,242 shares. The 52-week high of the share price is $285 and the company has a market cap of $3,473 M . The 52-week low of the share price is at $89.76.
Company has been under the radar of several Street Analysts.Intercept Pharmaceuticals Inc is Downgraded by Morgan Stanley to Underweight. Earlier the firm had a rating of Equal-Weight on the company shares. The Rating was issued on Apr 8, 2016.Intercept Pharmaceuticals Inc is Upgraded by Wells Fargo to Outperform. Earlier the firm had a rating of Market Perform on the company shares. The Rating was issued on Apr 5, 2016.Intercept Pharmaceuticals Inc is Initiated by Goldman to Neutral. The Rating was issued on Mar 30, 2016.Intercept Pharmaceuticals Inc is Initiated by Credit Suisse to Outperform and the brokerage firm has set the Price Target at $200. The Rating was issued on Mar 30, 2016.
Intercept Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry. The Companys product candidate obeticholic acid (OCA) is a bile acid analog a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The Company is also developing other products INT-767 and INT-777 for the treatment of fibrosis and type 2 diabetes. OCA has been tested in five placebo-controlled clinical trials including a completed Phase III clinical trial in patients with primary biliary cirrhosis (PBC) and two Phase II clinical trials in patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). OCA met the primary efficacy endpoint in each of these trials with statistical significance.